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YAP is an oncoprotein whose expression
is elevated in various human cancers;
however, the development of potentially
therapeutic compounds targeting YAP
has been slow. Wang et al. report that
tankyrase inhibitors inhibit YAP
oncogenic activity by stabilizing
angiomotin family proteins via the
tankyrase-RNF146 axis.
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As the key effector in the Hippo pathway, YAP was
identified as an oncoprotein whose expression is
elevated in various human cancers. However, the
development of potentially therapeutic compounds
targeting YAP has been slow and limited. Here, we
find that tankyrase inhibitors suppress YAP activity.
This effect is mediated by anigomotin (AMOT) family
proteins. Tankyrases associate with AMOT family
proteins and promote their degradation through E3
ligase RNF146. By antagonizing tankyrase activity,
tankyrase inhibitors stabilize AMOT family pro-
teins, thereby suppressing YAP oncogenic functions.
Together, our studies not only demonstrate the tank-
yrase-RNF146-AMOT axis as an upstream pathway
regulating YAPbut also reveal a therapeutic opportu-
nity in targeting YAP for cancer treatment.INTRODUCTION
The evolutionarily conserved Hippo pathway plays fundamental
roles in tissue homeostasis and organ size control (Halder and
Johnson, 2011; Pan, 2010; Zhao et al., 2010). Genetic mutations
of Hippo pathway components lead to tissue/organ overgrowth
and eventually tumorigenesis, which suggests that the Hippo
pathway is a putative tumor suppressor pathway. In mammals,
the Hippo pathway is composed of kinase cascades (MST and
LATS), adaptor proteins (SAV1 for MST and MOB1 for LATS), a
downstream effector (YAP), and nuclear transcription factors
(TEADs). MST kinase phosphorylates and activates LATS kinase.
The activated LATS kinase phosphorylates YAP at serine 127,
providing the docking site for 14-3-3 proteins, which sequesters
YAP in the cytoplasm. On the other hand, un-phosphorylated
YAP translocates into the nucleus and functions as a transcrip-
tional co-activator with TEAD family transcription factors. The
YAP-TEAD transcriptional complex governs the transcription
of downstream genes involved in cell proliferation and anti-
apoptosis. The nuclear protein VGLL4 antagonizes the YAP-
TEAD complex and consequently inhibits YAP’s transactivation
activity (Jiao et al., 2014; Koontz et al., 2013; Zhang et al.,
2014). TAZ is a YAP paralog and is similarly regulated by the
Hippo pathway (Lei et al., 2008; Zhang et al., 2009), although524 Cell Reports 13, 524–532, October 20, 2015 ª2015 The AuthorsYAP and TAZ have exhibited different physiological functions
based on the phenotypes observed in genetically modified
mouse models (Kang et al., 2009; Makita et al., 2008).
As the key target in the Hippo pathway, YAP has been identi-
fied as an oncoprotein. Overexpression of YAP inmice led to liver
enlargement and liver cancer formation (Camargo et al., 2007;
Dong et al., 2007). Elevated expression of YAP has also been
identified in various human cancers (Dong et al., 2007; Harvey
et al., 2013; Mo et al., 2014). Notably, recent studies demon-
strated that YAP overexpression promoted resistance to
KRAS-, RAF-, and MEK-targeted cancer therapies (Kapoor
et al., 2014; Lin et al., 2015; Shao et al., 2014), highlighting the
need to target YAP for cancer treatment.
Efforts have been devoted to search for druggable targets
within the Hippo-YAP pathway in order to develop pharmacolog-
ical compounds that could inhibit YAP oncogenic activities. For
example, the small molecule verteporfin was identified as an
effective inhibitor of YAP because of its ability to block formation
of the TEAD-YAP transcriptional complex (Liu-Chittenden et al.,
2012). Moreover, recent studies identified GPCR receptors as
upstream regulators for the Hippo-YAP pathway (Miller et al.,
2012; Yu et al., 2012), which expanded the potential upstream
targets for YAP suppression. Intriguingly, PPxY (PY) motif-con-
taining proteins, angiomotin (AMOT) family proteins (Chan
et al., 2011; Wang et al., 2011; Zhao et al., 2011) and PTPN14
(Huang et al., 2013; Liu et al., 2013; Michaloglou et al., 2013;
Wang et al., 2012b) were also able to antagonize YAP oncogenic
functions by translocating YAP into the cytoplasm. This ability to
retain YAP in the cytosol is achieved through direct protein-pro-
tein interactions mediated by the AMOT/PTPN14-PY motif and
YAP-WW domains. Thus, modulating the levels of AMOT and
PTPN14 or the PY motif-WW domain interaction could be addi-
tional approaches for anti-YAP agents.
In this study, our aim was to identify other effective YAP-
targeting strategies. We identified tankyrase inhibitors as com-
pounds that potentially target YAP. Tankyrase inhibitors sup-
pressed a series of YAP-dependent oncogenic functions and
specifically targeted the three-dimensional (3D) acinar growth
of YAP-transformed MCF10A cells. Moreover, the tankyrase in-
hibitors stabilized AMOT family proteins by suppressing their
tankyrase-RNF146 axis-mediated degradation. These data not
only reveal tankyrases and RNF146 as regulators of the Hippo-
YAP pathway, but also indicate the potential therapeutic value
of employing tankyrase inhibitors to target YAP for cancer
treatment.
Figure 1. Tankyrase Inhibitors Suppressed YAP Activity
(A) XAV939 suppressed YAP/TEAD luciferase reporter activity. Luciferase reporter assay was performed in HeLa cells treated with XAV939 at indicated con-
centrations for 24 hr. pSV40-Renilla was used as internal control.
(B) XAV939 treatment partially translocated YAP from nucleus into cytoplasm. Low-densityMCF10A cells were treatedwith dimethyl solfoxide (DMSO) or XAV939
(10 mM) for 48 hr, and the percentages of nuclear YAP are shown. Nucleus is indicated by DAPI staining. M, merged. Scale bar, 20 mm.
(C and D) XAV939 treatment suppressed YAP transcriptional activity. The transcripts of YAP target genes were detected by qPCR in MCF10A (C) and HEK293A
(D) cells. Cells were treated with XAV939 (10 mM) for the indicated time periods.
(E and F) Tankyrase inhibitors suppressed YAP activities. YAP/TEAD-luciferase reporter activity (E), and the transcripts of YAP target genes (F) were detected in
cells treated with indicated inhibitors (10 mM) for 24 hr.
(G and H) Double knockdown of tankyrase 1 and 2 suppressed YAP activities. YAP/TEAD-luciferase reporter activity (G) and the transcripts of YAP target genes
(H) were detected in cells transduced with indicated short hairpin RNAs (shRNAs). For the luciferase reporter assay, HeLa cells were treated with XAV939 (10 mM)
for 24 hr. For all panels, *p < 0.05, **p < 0.01, and ***p < 0.001.RESULTS
Tankyrase Inhibitors Target YAP
To explore the translational potential of targeting the Hippo-YAP
pathway for cancer treatment, we performed a compound
screen using YAP-TEAD luciferase reporter assay and YAP
cellular localization as indications of YAP activity (Figure S1A).
Interestingly, we identified the compound XAV939 as a putative
inhibitor of YAP. XAV939 suppressed YAP/TEAD-based lucif-
erase reporter activity (Figure 1A) and partially translocated
YAP from the nucleus into cytoplasm in low-density MCF10A
cells (Figure 1B). Consistent with this finding, the transcription
of YAP target genes were also suppressed by XAV939 treatment
in both MCF10A and HEK293A cells (Figures 1C and 1D; Fig-
ure S1B). Moreover, similar inhibitory effect on YAP activity
mediated by XAV939 was also observed in several other typesCof cancer cell lines (Figure S1D). These data suggest that
XAV939 can suppress YAP activity.
XAV939 is a tankyrase inhibitor (Huanget al., 2009). Tankyrases
(TNKS1 and TNKS2) belong to the poly(ADP-ribose) polymerase
(PARP) family and are known to induce the poly-ADP
ribosylation (PARsylation) of their substrates (Riffell et al., 2012).
The substrate is recognized by tankyrases through its tankyr-
ase-binding domain (TBD), which has the consensus amino
acid sequence RxxPxG (Guettler et al., 2011). The tankyrase-
mediated PARsylation leads to at least two fates for the
substrate: change of subcellular localization or proteasome-
dependent degradation. It was reported that the E3 ligase
RNF146 recognizes the tankyrase-mediated PAR modification
of substrates and is responsible for their ubiquitinationanddegra-
dation (Zhang et al., 2011). Tankyrases regulate diverse cellular
functions through their substrates (Riffell et al., 2012), such asell Reports 13, 524–532, October 20, 2015 ª2015 The Authors 525
telomere length by degrading TRF1 (Smith et al., 1998), mitosis
progress by changing the localization for Miki (Ozaki et al.,
2012), bone development by degrading 3BP2 (Levaot et al.,
2011), andWnt signaling by degrading AXIN (Huang et al., 2009).
To validate the role of tankyrase inhibition in YAP suppression,
we examined the effect of two other tankyrase inhibitors, JW55
andWIKI4. Just like XAV939, these two tankyrase inhibitors sup-
pressed YAP/TEAD luciferase reporter activity (Figure 1E) and
the transcription of YAP target genes (Figure 1F), while the con-
trol, PARP inhibitor olaparib, had no effect on these YAP-depen-
dent assays. These data suggest that tankyrase inhibitors are
putative YAP inhibitors. Moreover, loss of tankyrase 1/2 not
only suppressed YAP/TEAD luciferase reporter activity (Fig-
ure 1G) and transcription of YAP target genes (Figure 1H), but
also attenuated the inhibitory effect of XAV939 (Figure 1G).
These results indicate that tankyrases are positive regulators of
YAP and could be used to target this oncoprotein.
Tankyrases Interact with Angiomotin Family Proteins in
the Hippo Pathway
To determine the underlying mechanisms for the tankyrase-inhi-
bition-mediated YAP suppression, we isolated TNKS1-associ-
atedprotein complexes fromHEK293Tcells using tandemaffinity
purification followed by mass spectrometry analysis. Surpris-
ingly, all members of the angiomotin protein family (AMOT,
AMOTL1, andAMOTL2)were identifiedon theprey list (Figure 2A;
Table S1). The interactions between AMOT family proteins and
tankyrase1wereconfirmedbyendogenous immunoprecipitation
assay (Figure 2B). As predicted, the known tankyrase substrate
AXIN2 interacted with tankyrase 1, whereas another PY-motif
containing protein PTPN14 did not (Figure 2B). The specific inter-
action between tankyrase 1 and AMOT was further confirmed
by using other components of the Hippo pathway (Figure 2C).
Moreover, both tankyrase 1 and tankyrase 2 bound to AMOTL2
(Figure 2D). Of the several TBDs that were predicted for each
AMOT family protein (Figure 2E) (Guettler et al., 2011), the first
predicted TBD in each AMOT family protein was confirmed to
mediate the protein’s association with tankyrase 1 (Figure 2F).
This TBD is highly conserved among AMOT family proteins and
among different species (Figure 2G). Together, these data sug-
gest that AMOT family proteins are bona-fide binding partners
of tankyrases. Of note, the interaction between AMOT family pro-
teins and YAP was independent of this TBD, since AMOT TBD-
deleted mutants still associated with YAP (Figure S2A).
Tankyrases Promote Degradation of AMOT Family
Proteins through E3 Ligase RNF146
Given that AMOT family proteins are found to associate with
tankyrases, we examined whether AMOT family proteins can
be ribosylated by tankyrases. Indeed, AMOT protein was ribosy-
lated in vivo (Figure 3A). Next, we tested whether AMOT protein
could be ribosylated by tankyrases. As shown in Figure 3B,
tankyrase 1 not only ribosylated itself, but also ribosylated
AMOT protein, as indicated by the biotinylated NAD+ through
in vitro ribosylation assay. These results indicate that AMOT pro-
teins could be ribosylated by tankyrases.
To examine the regulation of AMOT family proteins by tank-
yrases, we found that tankyrase 1, but not its enzyme-inactive526 Cell Reports 13, 524–532, October 20, 2015 ª2015 The Authorsmutant (H1184A/E1291A; tankyrase 1-PD), promoted ubiquiti-
nation of all the AMOT family proteins (Figure 3C). Notably, we
did not detect any localization change of AMOT family proteins
with tankyrase 1 overexpression (data not shown), suggesting
that tankyrases may only modulate the stability of AMOT family
proteins. Moreover, compared to wild-type AMOT, deletion of
the TBD stabilized the AMOT protein (Figure 3D), which further
confirmed that tankyrases are involved in the regulation of
AMOT family protein stability.
Given that the E3 ligase RNF146 has been shown to recog-
nize tankyrase substrate and promote its proteasome-depen-
dent degradation (Zhang et al., 2011), we next examined the
role of RNF146 in the regulation of AMOT family proteins.
Indeed, loss of tankyrase1 and 2 stabilized all the AMOT family
proteins (Figure 3E). Similar findings were observed in RNF146
knockdown cells (Figures 3F and 3G). The WWE domain of
RNF146, which has been shown to recognize the ADP-ribosy-
lated proteins (Zhang et al., 2011), was required for the associ-
ation between RNF146 and AMOT family proteins (Figures S2B
and S2C). Moreover, overexpression of RNF146 induced the
ubiquitination of AMOT protein, which was suppressed by
XAV939 treatment (Figure S2D). In addition, loss of RNF146 in-
hibited the ubiquitination of AMOT protein (Figure S2E). These
data suggest that RNF146 is an E3 ligase for AMOT proteins.
Loss of RNF146 also inhibited the transcription of YAP down-
stream target genes (Figure 3H), suggesting the positive role
of RNF146 in YAP regulation. Together, these data indicate
that the tankyrase-RNF146 axis controls the stability of AMOT
family proteins.
Tankyrase Inhibitors Stabilize AMOT Family Proteins
The observation that the tankyrase-RNF146 axis promoted the
degradation of AMOT family proteins (Figure 3) suggested that
targeting tankyrases with tankyrase inhibitors would stabilize
AMOT proteins. Notably, treatment with tankyrase inhibitor
XAV939 specifically increased the levels of all the AMOT family
proteins but did not affect other Hippo pathway components
(Figures 4A and S1C). Moreover, the levels of AMOT family pro-
teins were regulated by XAV939 treatment in a dose-dependent
manner (Figure S3A) and also in a time-dependent manner (Fig-
ure 4B). The other two tankyrase inhibitors, JW55 and WIKI4,
also stabilized AMOT family proteins, while this was not the
case for PARP inhibitor olaparib (Figure 4C). These data suggest
that, in the Hippo pathway, tankyrase inhibitors specifically regu-
late AMOT family protein levels.
Consistently, XAV939 treatment only stabilized wild-type
AMOTproteins but not their TBD1-deletedmutants (Figure S3C).
Loss of RNF146 attenuated the effect of XAV939 on the stabiliza-
tion of AMOT family proteins (Figure S3D). Notably, AMOT family
proteins were previously shown to be regulated by NEDD4.2 E3
ligase (Skouloudaki and Walz, 2012; Wang et al., 2012a). How-
ever, another known NEDD4.2 substrate, SMAD2 (Kuratomi
et al., 2005), and NEDD4.2 upstream regulator SGK1 (Lamothe
and Zhang, 2013) were not affected by XAV939 treatment (Fig-
ure S3E), suggesting that NEDD4.2 E3 may not be involved
in this process. Together, these results further demonstrated
that tankyrase inhibitors stabilize AMOT family proteins through
tankyrase-RNF146 axis.
Figure 2. Tankyrases Associated with Angiomotin Family Proteins
(A) Association of angiomotin family proteins with tankyrase 1 was identified by tandem affinity purification-mass spectrometry (TAP-MS) in HEK293T cells. Bait
protein is marked in red. Identified angiomotin family proteins AMOT, AMOTL1, and AMOTL2 are marked in blue. The left row of numbers represents unique
peptide number/total peptide number. The known tankyrase 1 (TNKS1)-associated proteins are indicated.
(B) TNKS1 interacted with AMOT proteins. Endogenous immunoprecipitation (IP) was performed using extract prepared from HEK293T cells; normal rabbit
immunoglobulin G (IgG) was taken as control.
(C) TNKS1 specifically associated with AMOT in the Hippo pathway. Myc-tagged TNKS1 was co-expressed with indicated SFB-tagged proteins in HEK293T
cells, and cell lysates were subjected to pull-down assays.
(D) Both TNKS1 and TNKS2 associated with AMOTL2. Myc-tagged TNKS1 or TNKS2 was co-expressed with indicated SFB-tagged proteins in HEK293T cells,
and cell lysates were subjected to pull-down assays.
(E) The predicted tankyrase-binding domains (TBD) for AMOT family proteins are listed. The key amino acids for each TBD are indicated in red.
(F) The first predicted TBDwas identified as the bona-fide TBD for each AMOT proteins.Myc-tagged TNKS1was co-expressedwith indicated SFB-tagged AMOT
proteins or their TBD-deleted mutants in HEK293T cells, and cell lysates were subjected to pull-down assays.
(G) The sequence alignments for the TBD in AMOT family proteins from different species are shown. The key amino acids for each TBD are indicated in red.Tankyrase Inhibitors Target YAP through AMOT Family
Proteins
AMOT proteins have been shown to inhibit YAP’s activities by
translocating YAP from nucleus into cytoplasm, which provides
a potential mechanism for the tankyrase-inhibition-mediated
YAP suppression through stabilization of all AMOT proteins.
As a matter of fact, overexpression of AMOT family proteins,C(i.e., AMOTL2), which mimics the stabilization of AMOT proteins
by tankyrase inhibitors, neutralized the capacity of XAV939 to
suppress YAP/TEAD luciferase activity (Figures 4D and S3H).
Moreover, loss of AMOTL1 and AMOTL2 attenuated XAV939’s
inhibitory effect on YAP, as indicated by YAP/TEAD-luciferase
reporter activity (Figure 4E) and the transcription of YAP target
genes (Figures 4F and 4G). These results demonstrate thatell Reports 13, 524–532, October 20, 2015 ª2015 The Authors 527
Figure 3. Tankyrase-RNF146 Axis Promoted the Degradation of AMOT Proteins
(A) AMOT protein was ribosylated in vivo. Endogenous immunoprecipitation (IP) was performed using extract prepared from HEK293T cells containing ADP-HPD
(5 mM); normal rabbit IgG was taken as control. PAR, poly-ADP ribosylation polymer antibody.
(B) Tankyrase 1 (TNKS1) promoted ribosylation of AMOT protein in vitro. In vitro ribosylation assay was performed and the ribosylated proteins were indicated by
the incorporation of biotinylated NAD+ and detected by anti-biotin antibody.
(C) Tankyrase 1 (TNKS1) induced the ubiquitination of AMOT proteins. HA-tagged ubiquitin (Ub) was co-expressed with indicated proteins in HEK293T cells for
24 hr. Cells were treated with proteasome inhibitor MG132 (10 mM) for 6 hr and subjected to immunoprecipitation (IP) assay. TNKS1-PD is the inactive mutant for
TNKS1.
(D) Tankyrase-binding domain (TBD) deletionmutation stabilized the AMOT protein. AMOT or its TBD-deletedmutant (AMOT-DTBD1) was expressed in HEK293T
cells for 24 hr. Cells were treated with cycloheximide (CHX; 100 mg/mL) and collected at different time points for western blotting.
(E) Loss of tankyrase 1/2 stabilized AMOT proteins. Indicated proteins were detected in control and tankyrase 1/2 knockdown (shRNA-transduced) HEK293A
cells by western blotting.
(F andG) Loss of RNF146 stabilized AMOT proteins. RNF146 knockdown efficiencywas shown by qPCR (F). Indicated proteins were detected in control and three
groups of RNF146 shRNA-transduced HEK293A cells by western blotting (G).
(H) Loss of RNF146 suppressed the transcripts of YAP target genes. The transcripts were detected by qPCR in control and three groups of RNF146 shRNA-
transduced HEK293A cells.
For (F) and (H), **p < 0.01 and ***p < 0.001.tankyrase inhibitors target YAP by stabilizing AMOT family
proteins.
Notably, XAV939 treatment did not affect YAP phosphoryla-
tion at S127 or the kinase activity of LAST andMST (Figure S3G),
suggesting that XAV939 targets YAP independent of YAP phos-
phorylation. These findings are consistent with previous studies
that AMOT family proteins suppressed YAP activity by translo-
cating YAP from nucleus into cytoplasm through direct protein-
protein interaction but independent of YAP phosphorylation
status (Chan et al., 2011; Wang et al., 2011; Zhao et al., 2011).
Moreover, overexpression AMOT protein also did not affect
YAP phosphorylation at S127 (Figure S3H).
Tankyrase Inhibitors Inhibit the 3D Growth of
YAP-Transformed MCF10A Cells
YAP was first identified as an oncoprotein with the capacity to
transform normal mammary epithelial MCF10A cells (Overholt-528 Cell Reports 13, 524–532, October 20, 2015 ª2015 The Authorszer et al., 2006), which provides a model to study YAP’s onco-
genic functions. We found that, consistent with previous finding
(Overholtzer et al., 2006), overexpression of YAP increased the
anchorage-independent growth of MCF10A cells, and this was
suppressed by the tankyrase inhibitor XAV939 treatment (Fig-
ures 5A and 5B). Moreover, in mammary epithelial MCF10A
cells, which form acinar structures when grown in 3D condi-
tions, recapitulating numerous features of breast epithelium
in vivo (Debnath et al., 2003), overexpression of YAP led to
the formation of branch-like invasive acini in matrigel (Fig-
ure 5C), confirming YAP’s oncogenic activities (Overholtzer
et al., 2006). Intriguingly, XAV939 suppressed this formation
of invasive acini induced by YAP overexpression in 3D matrigel
culture, decreasing both the number and size of invasive acini
(Figures 5C–5E). Notably, XAV939 had only a moderate effect
on acini growth for vector-transduced MCF10A cells (Fig-
ure 5C), suggesting that tankyrase inhibitors could specifically
Figure 4. Tankyrase Inhibitors Targeted YAP through AMOT Family Proteins
(A) XAV939 treatment specifically increased the levels of AMOT family proteins in the Hippo pathway. Western blot was performed in DMSO (control)- and
XAV939-treated HEK293A cells with indicated antibodies.
(B) XAV939 treatment increased the levels of AMOT family proteins in a time-dependent manner. HEK293A cells treated with XAV939 (10 mM) were collected at
indicated time points for western blotting with indicated antibodies.
(C) AMOT proteins were stabilized by treatment with tankyrase inhibitors. HEK293A cells treated with the indicated inhibitors (10 mM) for 24 hr were subjected to
western blotting with indicated antibodies.
(D) Overexpression of AMOTL2 attenuated XAV939-induced suppression of YAP. YAP/TEAD luciferase reporter assay was performed in HeLa cells transfected
with vector or SFB-AMOTL2 and treated with indicated doses of XAV939 for 24 hr. pSV40-Renilla was used as internal control.
(E–G) Loss of AMOTL1/2 attenuated XAV939-induced suppression of YAP. Control and AMOTL1/2 shRNA-transduced HeLa and MCF10A cells were subjected
to YAP/TEAD luciferase reporter assay (E) and transcription analysis of YAP target genes by qPCR (G), respectively. The downregulation of AMOTL1 andAMOTL2
in MCF10A cells is shown (F). Both HeLa and MCF10A cells were pre-treated with XAV939 (10 mM) for 24 hr before collection.
For (D), (E), and (G), *p < 0.05 and ***p < 0.001.target YAP in 3D growth with minimal effect on normal acini
formation.
To confirm the role of the tankyrase-RNF146 axis in YAP-
dependent invasive acini formation, we knocked down RNF146
in both vector- and YAP- overexpressingMCF10A cells and sub-
jected those cells to 3D culture (Figure 5F). Similar to treatment
with XAV939, loss of RNF146 specifically suppressed invasive
acini formation of YAP-transformed MCF10A cells, decreasing
both the number and size of YAP-induced invasive acini (Figures
5F–5H). Similarly, loss of RNF146 had only a slight effect on acini
formation of cells transfected with vector control (Figure 5F).
These data indicate that the tankyrase-RNF146 axis was
required for YAP-dependent invasive acini formation in 3D cul-
ture and that tankyrase inhibitors could be utilized to target
YAP-dependent oncogenesis.CDISCUSSION
In this study, we discovered that tankyrase inhibitors as a group
of compounds target YAP’s oncogenic activities. Interestingly,
the tankyrase inhibitors specially suppressed YAP-induced
MCF10A invasive acini formation but did not affect normal
MCF10A acini formation, suggesting their therapeutic potential
in the treatment of YAP-dependent cancers. This inhibitory effect
may not require the Wnt pathway, since MCF10A cells have very
lowWnt activity (Figure S4A), and it is difficult to detect AXIN pro-
tein expression inMCF10A cells (Figure S4B). Notably, tankyrase
inhibitors only exhibited moderate inhibitory effect on the growth
of YAP-overexpressing MCF10A cells in 2D culture, indicating
that the microenvironment plays a critical role in this process,
an implication that deserves further investigation.ell Reports 13, 524–532, October 20, 2015 ª2015 The Authors 529
Figure 5. Tankyrase Inhibitors Targeted the Oncogenic Functions of YAP
(A and B) XAV939 treatment suppressed the anchorage-independent growth of YAP-transformed MCF10A cells. Vector- or YAP-overexpressing MCF10A cells
were subjected to soft agar assay and treatedwith DMSOor XAV939 (30 mM) for 4 weeks. Representative colonies are shown (A) andwere quantified (B). Data are
presented as means ± SD from three independent experiments.
(C–E) XAV939 treatment inhibited YAP-induced MCF10A invasive acini formation. Vector- or YAP-overexpressing MCF10A cells were subjected to 3D culture in
matrigel and were treated with DMSO or XAV939 (30 mM) for 5 days. Representative acini are shown (C). The percentage (D) and the size (E) of invasive acini are
quantified. Data are presented as means ± SD from three independent experiments.
(F–H) Loss of RNF146 suppressed YAP-induced MCF10A invasive acini formation. Vector- or YAP-overexpressing MCF10A cells transduced with control or one
of three RNF146 shRNAswere subjected to 3D culture inmatrigel and treatedwith DMSOor XAV939 (30 mM) for 5 days. Representative acini (F) and quantification
of percentage (G) and size (H) of invasive acini are shown.
Data are presented as means ± SD from three independent experiments. For all the panels, ns, not significant; ***p < 0.001; scale bar, 100 mm.AMOT family proteins are known to be part of the Hippo
pathway. AMOT family proteins employ at least twomechanisms
to negatively regulate YAP/TAZ. First, AMOT family proteins
translocate YAP/TAZ from nucleus into cytoplasm through direct
protein-protein interaction, which is independent of YAP/TAZ
phosphorylation status (Chan et al., 2011; Wang et al., 2011;
Zhao et al., 2011). Second, AMOT family proteins have also
been shown to activate LATS kinase and suppress YAP/TAZ’s
activity in a phosphorylation-dependent manner (DeRan et al.,
2014; Paramasivam et al., 2011). In addition, AMOT proteins
form multiple complexes with other Hippo components. For
example, LATS kinase associates with and phosphorylates
AMOT proteins, which, in turn, stabilizes AMOT proteins (Adler
et al., 2013), and disrupts the association between AMOT pro-
teins and actin cytoskeleton (Chan et al., 2013; Dai et al.,
2013). AMOT proteins also associate with NF2/Merlin and regu-
late Ras-MAPK pathway (Yi et al., 2011). In this study, we
showed that tankyrase inhibitors can stabilize AMOT family pro-
teins by interrupting the tankyrase-RNF146 axis, which not only
advances our understanding about the regulation of AMOT fam-
ily proteins, but also provides useful tools, i.e., tankyrase inhibi-
tors, to further study this protein family.
The discovery of the role of tankyrase inhibitors in YAP regula-
tion led to identification of the RNF146-tankyrase-AMOT axis as530 Cell Reports 13, 524–532, October 20, 2015 ª2015 The Authorsan upstream signaling pathway regulating YAP in the Hippo
pathway. Previously, we and others showed that tankyrase tar-
geted AXIN (Huang et al., 2009) and PTEN (Li et al., 2015) for
degradation and that tankyrase inhibitors stabilized these tumor
suppressors. Together with our data presented here, these
studies highlight the therapeutic potential of tankyrase inhibitors
in cancer, since they target at least three different oncogenic
proteins/pathways (YAP, Wnt, and AKT). Besides, two tankyrase
inhibitors (JW55 and G007-LK) have shown excellent oral avail-
ability and plasma/tissue distribution in mice (Lau et al., 2013;
Waaler et al., 2012), making them likely candidate compounds
for future translational studies.EXPERIMENTAL PROCEDURES
The information about antibody, cell culture, plasmid construction, immuno-
fluorescent staining, tandem affinity purification, mass spectrometry, and
reverse transcription in this study is described in the Supplemental Experi-
mental Procedures.
In Vitro Ribosylation Assay
Recombinant baculovirus-derived GST-TNKS1 (amino acids 1000–1328)
(0.2 mg, Sigma-Aldrich #SRP0422) and HEK293T-purified SFB-AMOT pro-
teins were incubated in 30 ml reaction buffer (50 mM Tris-HCl [pH 8.0],
4 mM MgCl2, 0.2 mM DTT) with or without 25 mM biotinylated NAD+
(Trevigen) at 25C for 30 min. Reactions were terminated and subjected to
western blotting.
Anchorage Independent Growth on Soft Agar
MCF10A cells (2 3 104) transduced with HA-Flag vector or HA-Flag YAP con-
structs were added to growth medium (1.5 ml) of growth medium with 0.33%
agar and layered onto beds of 0.5% agar (2ml) in six-well plates. Cells were fed
with medium (1 ml) with 0.33% agar every 7 days for 4 weeks, after which col-
onies were photographed. Assays were duplicated in three independent
experiments.
Three-Dimensional Culture of MCF10A Cell for Acini Formation
MCF10A cells (53 103) stably transfected with HA-Flag vector or HA-Flag YAP
constructs were grown in growth factor-reduced matrigel matrix in the 8-well
chamber slide system (Fisher Scientific). Cultured cells were analyzed for inva-
sive acini after 5 days of growth in matrigel, and at least four replicates were
performed as described (Debnath et al., 2003). DMSO or XAV939 (30 mM)
was added to the medium and refreshed every 2 days.
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